Loading...

Rubius Therapeutics

DB:5RT
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
5RT
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • Rubius Therapeutics has significant price volatility in the past 3 months.
5RT Share Price and Events
7 Day Returns
-14.8%
DB:5RT
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-
DB:5RT
-7.4%
DE Biotechs
-5.6%
DE Market
5RT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Rubius Therapeutics (5RT) -14.8% -2% 17.6% - - -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • No trading data on 5RT.
  • No trading data on 5RT.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

5RT Value

 Is Rubius Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Rubius Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €13.882.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Rubius Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Rubius Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:5RT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.27
NasdaqGS:RUBY Share Price ** NasdaqGS (2019-04-24) in USD $16.53
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Rubius Therapeutics.

DB:5RT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:RUBY Share Price ÷ EPS (both in USD)

= 16.53 ÷ -2.27

-7.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rubius Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Rubius Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Rubius Therapeutics's expected growth come at a high price?
Raw Data
DB:5RT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.28x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-31.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Rubius Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Rubius Therapeutics's assets?
Raw Data
DB:5RT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.96
NasdaqGS:RUBY Share Price * NasdaqGS (2019-04-24) in USD $16.53
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:5RT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:RUBY Share Price ÷ Book Value per Share (both in USD)

= 16.53 ÷ 4.96

3.33x

* Primary Listing of Rubius Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rubius Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Rubius Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Rubius Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

5RT Future Performance

 How is Rubius Therapeutics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-31.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Rubius Therapeutics expected to grow at an attractive rate?
  • Unable to compare Rubius Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Rubius Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Rubius Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:5RT Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:5RT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -31.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:5RT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:5RT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 -162
2022-12-31 -175
2021-12-31 -175 -256
2020-12-31 0 -165 -202 3
2019-12-31 0 -132 -151 3
DB:5RT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -58 -89
2018-09-30 -48 -80
2018-06-30 -35 -65
2018-03-31 -30 -55
2017-12-31 -22 -45
2016-12-31 -10 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Rubius Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Rubius Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:5RT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Rubius Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5RT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 -2.88 -2.88 -2.88 1.00
2020-12-31 -2.34 -2.26 -2.49 3.00
2019-12-31 -1.94 -1.73 -2.14 3.00
DB:5RT Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.27
2018-09-30 -3.60
2018-06-30 -7.62
2018-03-31 -6.65
2017-12-31 -5.55
2016-12-31 -1.63

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Rubius Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Rubius Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Rubius Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

5RT Past Performance

  How has Rubius Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Rubius Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Rubius Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Rubius Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Rubius Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Rubius Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Rubius Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5RT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -89.20 39.89 51.77
2018-09-30 -79.53 38.19 41.83
2018-06-30 -65.09 30.84 33.59
2018-03-31 -54.53 26.73 27.20
2017-12-31 -44.50 22.04 21.23
2016-12-31 -11.76 2.45 8.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Rubius Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Rubius Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Rubius Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Rubius Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Rubius Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

5RT Health

 How is Rubius Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Rubius Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Rubius Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Rubius Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Rubius Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Rubius Therapeutics Company Filings, last reported 3 months ago.

DB:5RT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 393.01 70.29 404.05
2018-09-30 411.01 30.12 408.87
2018-06-30 172.69 22.38 181.73
2018-03-31 186.16 16.62 192.62
2017-12-31 96.97 5.44 104.29
2016-12-31 2.01 3.92 6.83
  • Rubius Therapeutics's level of debt (17.9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Rubius Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Rubius Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Rubius Therapeutics has sufficient cash runway for 2.9 years if free cash flow continues to grow at historical rates of 76.9% each year.
X
Financial health checks
We assess Rubius Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Rubius Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

5RT Dividends

 What is Rubius Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Rubius Therapeutics dividends.
If you bought €2,000 of Rubius Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Rubius Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Rubius Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:5RT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:5RT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Rubius Therapeutics has not reported any payouts.
  • Unable to verify if Rubius Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Rubius Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Rubius Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Rubius Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Rubius Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Rubius Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

5RT Management

 What is the CEO of Rubius Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Pablo Cagnoni
AGE 55
TENURE AS CEO 0.8 years
CEO Bio

Dr. Pablo J. Cagnoni, M.D. has been the Chief Executive Officer of Rubius Therapeutics, Inc. since June 6, 2018 and serves as its Director since 2018. Dr. Cagnoni serves as President of Rubius Therapeutics, Inc. He is a Co-Founder of Tizona Therapeutics, Inc. and served as its Chief Executive Officer and President. He is the Executive Chairman of Blade Therapeutics. He served as a Managing Director at MPM Capital since May 20, 2015. He served as the President of Onyx Pharmaceuticals, Inc. since October 2013, where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. Dr. Cagnoni joined Onyx in March 2013. He served as an Executive Vice President of Global Research & Development and Technical Operations at Onyx Pharmaceuticals, Inc. since March 2013. At Onyx, he had global strategic oversight and accountability of the business from early product development to commercialization. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology, where he was responsible for all clinical development, clinical operations, clinical pharmacology and correlative sciences activities for the oncology development pipeline. He served as the Chief Medical Officer and Senior Vice President of Allos Therapeutics, Inc. from March 20, 2007 to September 30, 2009. He led Allos Therapeutics Inc.'s clinical development functions, including clinical operations, medical affairs and biometrics. From 2004 to 2007, he held several key management positions with OSI Pharmaceuticals, Inc., served as the Chief Medical Officer and Vice President of Clinical Research and Medical Affairs since December 18, 2006. He oversaw all of the clinical development and medical affairs activities of OSI Pharmaceuticals's oncology portfolio which includes further development of its flagship product Tarceva. He has almost 20 years of clinical development experience in oncology in both the biotechnology and the academic settings. He served as Vice President of Medical Affairs, Clinical Development and Translational Research of Osi Pharmaceuticals Inc. and served as an Interim Senior Medical Officer For Oncology Clinical Development since May 1, 2005. He served as Allos Therapeutics, Inc.'s Consultant for clinical development and regulatory activities since August 2004. He served at Allos Therapeutics Inc., as Vice President of Clinical Development from March 2003 to August 2004 and served as Senior Medical Director from June 2002 to February 2003 and as a Director of Clinical Development from July 2001 to June 2002. Prior to Allos Therapeutics Inc., he served as an Assistant Professor of Medicine in the Division of Oncology at the University of Colorado, where he also served as an Assistant Director of the Pharmacology Laboratory and Member of the Bone Marrow Transplant Program and a Member of the University of Colorado Cancer Center. He has been a Director of Lycera Corp. since March 13, 2017. Dr. Cagnoni serves as a Director of Harpoon Therapeutics. He has been an Independent Director of CRISPR Therapeutics AG since December 2015. He also serves as a Director of Tizona Therapeutics, Inc. He has authored over 50 publications, numerous book chapters and has lectured extensively in several areas related to clinical oncology and drug development. He has 25-year career as an oncologist and biopharmaceutical innovator.Over of the course of his career, Dr. Cagnoni has played a key role in the development, approval and/or commercialization of several life-changing medicines, including Afinitor®, Blincyto® Exjade®, Folotyn® Glivec®, Jakavi®, Kyprolis®, Signifor®, Tarceva®, Tasigna® and Zykadia® among them. Dr. Cagnoni earned his M.D. from the University Buenos Aires School of Medicine and he completed his fellowship in Hematology and Oncology at The Mount Sinai Medical Center, New York and in Bone Marrow Transplantation at the University of Colorado. Dr. Cagnoni completed a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center. He graduated Summa Cum Laude from the University of Buenos Aires Medical School.

CEO Compensation
  • Insufficient data for Pablo to compare compensation growth.
  • Insufficient data for Pablo to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Rubius Therapeutics management team in years:

1.6
Average Tenure
55
Average Age
  • The average tenure for the Rubius Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

David Epstein

TITLE
Executive Chairman
COMPENSATION
$5M
AGE
56

Christopher Carpenter

TITLE
Chief Medical Officer
COMPENSATION
$3M
AGE
62
TENURE
1.6 yrs

Pablo Cagnoni

TITLE
CEO, President & Director
AGE
55
TENURE
0.8 yrs

Andrew Oh

TITLE
Chief Financial Officer
AGE
46
TENURE
1.3 yrs

Joanne Protano

TITLE
Senior VP of Finance & Operations
AGE
49

Lori Melançon

TITLE
Vice President of Corporate Communications & Investor Relations

Mark Boshar

TITLE
Vice President of Legal Affairs
TENURE
1.7 yrs

Nathan Dowden

TITLE
Senior VP of Strategy & Corporate Development
TENURE
2.9 yrs

Theo Proukou

TITLE
Senior VP & Chief People Officer
TENURE
2.3 yrs

Tom Wickham

TITLE
Senior Vice President of Discovery
Board of Directors Tenure

Average tenure and age of the Rubius Therapeutics board of directors in years:

1.8
Average Tenure
61
Average Age
  • The average tenure for the Rubius Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Pablo Cagnoni

TITLE
CEO, President & Director
AGE
55
TENURE
0.8 yrs

Michael Rosenblatt

TITLE
Director
AGE
70
TENURE
4.3 yrs

David Epstein

TITLE
Executive Chairman
COMPENSATION
$5M
AGE
56
TENURE
2.3 yrs

Noubar Afeyan

TITLE
Director
AGE
55
TENURE
6.3 yrs

Jon Symonds

TITLE
Director
AGE
59
TENURE
1.1 yrs

Harvey Lodish

TITLE
Scientific Advisory Board
COMPENSATION
$24K
TENURE
1.2 yrs

Bob Langer

TITLE
Director & Member of Scientific Advisory Board
COMPENSATION
$28K
AGE
69
TENURE
4.3 yrs

Roger Pomerantz

TITLE
Director
AGE
61
TENURE
4.3 yrs

Francis Cuss

TITLE
Director
AGE
63
TENURE
1.3 yrs

Cathy Sohn

TITLE
Director
AGE
65
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
23. Jul 18 Buy Catherine Sohn Individual 20. Jul 18 20. Jul 18 2,500 €19.64 €49,111
23. Jul 18 Buy Roger Pomerantz Individual 20. Jul 18 20. Jul 18 100 €19.64 €1,964
23. Jul 18 Buy Francis Cuss Individual 20. Jul 18 20. Jul 18 10,000 €19.64 €196,443
23. Jul 18 Buy Jonathan Symonds Individual 20. Jul 18 20. Jul 18 25,000 €19.64 €491,108
X
Management checks
We assess Rubius Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Rubius Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

5RT News

Simply Wall St News

5RT Company Info

Description

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Details
Name: Rubius Therapeutics, Inc.
5RT
Exchange: DB
Founded: 2013
$1,179,300,153
79,846,695
Website: http://www.rubiustx.com
Address: Rubius Therapeutics, Inc.
399 Binney Street,
Suite 300,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS RUBY Common Stock Nasdaq Global Select US USD 18. Jul 2018
DB 5RT Common Stock Deutsche Boerse AG DE EUR 18. Jul 2018
MUN 5RT Common Stock Boerse Muenchen DE EUR 18. Jul 2018
Number of employees
Current staff
Staff numbers
142
Rubius Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 23:41
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/16
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.